[Improvement of the quality of life in patients with non-operable pancreatic cancer treated with polyplatillen].
The authors summarize in the article experience of a new anticancer drug Polyplatillen use in the chemotherapy of advanced pancreatic cancer. Polyplatillen use in the palliative chemotherapy in the patients with advanced pancreatic cancer permits to realize a control of pain and stabilize an ECOG status. Tendency to the improvement of total survival during an early period was registered in the group of patients with advanced pancreatic cancer who were treated with Polyplatillen.
Iatsenko
L D
LD
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D018736:DNA Adducts / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D017567:Karnofsky Performance Status; D009367:Neoplasm Staging; D010146:Pain / Q000188:drug therapy; D010166:Palliative Care / Q000379:methods*; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000523:psychology; D011788:Quality of Life
D000970:Antineoplastic Agents; D018736:DNA Adducts; C057270:cisplatin-DNA adduct; D002945:Cisplatin